Plain-English fact sheet
Plecanatide
Also known as Trulance, uroguanylin analog
Plecanatide mimics the intestinal peptide uroguanylin and acts locally to improve bowel symptoms in adults with specific constipation disorders.
Quick answer
Plecanatide is FDA approved as Trulance for adults with chronic idiopathic constipation or irritable bowel syndrome with constipation. It is not approved for general gut health, detoxification, inflammation, or tissue repair.
By the PeptideFactSheets Editorial Team. Claims are source-checked under our editorial policy; clinician review is identified only when a named reviewer is shown.
What is Plecanatide?
Plecanatide is a 16-amino-acid analog of uroguanylin that activates guanylate cyclase-C on the intestinal surface.
Like linaclotide, it is minimally absorbed and its evidence is tied to local bowel and abdominal-symptom outcomes.
Why are people interested in it?
It offers a second approved peptide approach to gut-surface guanylate cyclase-C signaling.
Comparing it with linaclotide illustrates why related mechanisms still require product-specific efficacy and safety evidence.
Current regulatory status
Trulance is FDA approved for adults with chronic idiopathic constipation and adults with irritable bowel syndrome with constipation.
What is it approved for?
- Chronic idiopathic constipation and IBS with constipation in adults under the Trulance label
What is it being studied for?
Investigational areas
- Additional analyses of symptom response within the approved adult populations
Evidence snapshot
Multiple Phase 3 trials support the adult constipation indications. Evidence does not extend to children, unrelated digestive conditions, or broad gut-wellness claims.
Potential benefits being researched
- Controlled trials found higher composite response rates than placebo for IBS-C and chronic idiopathic constipation.
- Benefits are averages in defined trial populations and do not imply response for every person with constipation.
Potential does not mean proven. Study design, population, endpoint, and regulatory review matter.
Known or possible risks
- The label carries a boxed warning about serious dehydration in young pediatric patients and is not approved for pediatric use.
- Diarrhea is the most common adverse reaction and can be severe.
- It is contraindicated when mechanical gastrointestinal obstruction is known or suspected.
What we still do not know
- Long-term head-to-head effectiveness versus linaclotide and other approved options
- Reliable predictors of response and severe diarrhea
- Safety and effectiveness outside the approved adult populations
- Whether exploratory symptom composites translate into meaningful daily-life improvement
Plain-English takeaway
Plecanatide is a legitimate local gut peptide medicine for two adult constipation disorders—not a general-purpose gut or recovery peptide.
Research and reference links
Use these primary and reputable sources to verify status and read beyond this summary. Trial registries may list studies without proving a benefit.
- 1FDA prescribing information: Trulance
Approved adult indications, boxed warning, contraindications, and adverse reactions.
- 2Integrated analysis of two Phase 3 IBS-C trials
Controlled adult evidence for composite and individual symptom outcomes.
- 3Pooled Phase 3 analysis in older adults
Subgroup analysis illustrating efficacy, safety, and limitations in older participants.